Loading…

Prognostic Significance of c-erbB-2 mRNA in Ovarian Carcinoma

The oncogene specific mRNA of c-erbB-2 was detected by the S1 nuclease protection assay in 95 ovarian cancer specimens. In 79 primary carcinomas, we found 16 (20%) with strong expression, 13 (17%) with weak expression, 4 (5%) with very weak expression, and 46 (58%) with no expression. In 3 of 16 rec...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 1996-08, Vol.62 (2), p.268-277
Main Authors: Tanner, Berno, Kreutz, Elisabeth, Weikel, Wolfgang, Meinert, Rolf, Oesch, Franz, Knapstein, Paul Georg, Becker, Roger
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c410t-53e8be06e6268e64e8ca1b7d75d730a370d1e16e116c7bd4ac96ad2a3b24c1af3
cites
container_end_page 277
container_issue 2
container_start_page 268
container_title Gynecologic oncology
container_volume 62
creator Tanner, Berno
Kreutz, Elisabeth
Weikel, Wolfgang
Meinert, Rolf
Oesch, Franz
Knapstein, Paul Georg
Becker, Roger
description The oncogene specific mRNA of c-erbB-2 was detected by the S1 nuclease protection assay in 95 ovarian cancer specimens. In 79 primary carcinomas, we found 16 (20%) with strong expression, 13 (17%) with weak expression, 4 (5%) with very weak expression, and 46 (58%) with no expression. In 3 of 16 recurrencies (19%) a strong expression of c-erbB-2 mRNA was detected, in 2 (12%) weak expression was detected, and in 11 (69%) no expression of c-erbB-2 mRNA was detected. Kaplan–Meier analysis revealed no significant association between strong expression of c-erbB-2 mRNA and survival of the 79 patients with primary cancer. However, in the subgroup of patients with FIGO (International Federation of Gynecology and Obstetrics) stages III and IV (n= 60) a shorter median survival time (12 months) was obtained for patients with strong c-erbB-2 mRNA expression compared to patients with no, very weak, and weak c-erbB-2 mRNA expression (25 months,P= 0.04). In addition, strong expression of c-erbB-2 mRNA did not depend on histologic grade, histologic type, and FIGO stage. Adverse prognostic factors include histologic type (serous carcinoma), high grade, high stage (FIGO stages III and IV), and residual of tumor after surgery. From our results we conclude that for all patients (FIGO stages I–IV) strong expression of c-erbB-2 mRNA is not a prognostic parameter, but in the subpopulation of patients with FIGO stage III and IV only, an association between strong c-erbB-2 mRNA expression and shorter median survival time was found, although statistical significance was weak (P= 0.04).
doi_str_mv 10.1006/gyno.1996.0226
format article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1006_gyno_1996_0226</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825896902267</els_id><sourcerecordid>S0090825896902267</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-53e8be06e6268e64e8ca1b7d75d730a370d1e16e116c7bd4ac96ad2a3b24c1af3</originalsourceid><addsrcrecordid>eNp1zz1PwzAQBmALgUQprMweWBPOTuI4A0Op-JIqiviYrYt9qYzauLKrSv33JCpiY7rlfe_uYexaQC4A1O3q0IdcNI3KQUp1wiYCmipTumpO2QSggUzLSp-zi5S-AaAAISfs7i2GVR_Szlv-4Ve977zF3hIPHbcZxfY-k3zz_jrjvufLPUaPPZ9jtL4PG7xkZx2uE139zin7enz4nD9ni-XTy3y2yGwpYJdVBemWQJGSSpMqSVsUbe3qytUFYFGDEyQUCaFs3boSbaPQSSxaWVqBXTFl-XGvjSGlSJ3ZRr_BeDACzIg3I96MeDPih8LNsbDFZHHdxcHk01-rkFCXIIeYPsZoeH7vKZpkPQ185yPZnXHB_3fhB0mWbIs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prognostic Significance of c-erbB-2 mRNA in Ovarian Carcinoma</title><source>ScienceDirect Journals</source><creator>Tanner, Berno ; Kreutz, Elisabeth ; Weikel, Wolfgang ; Meinert, Rolf ; Oesch, Franz ; Knapstein, Paul Georg ; Becker, Roger</creator><creatorcontrib>Tanner, Berno ; Kreutz, Elisabeth ; Weikel, Wolfgang ; Meinert, Rolf ; Oesch, Franz ; Knapstein, Paul Georg ; Becker, Roger</creatorcontrib><description>The oncogene specific mRNA of c-erbB-2 was detected by the S1 nuclease protection assay in 95 ovarian cancer specimens. In 79 primary carcinomas, we found 16 (20%) with strong expression, 13 (17%) with weak expression, 4 (5%) with very weak expression, and 46 (58%) with no expression. In 3 of 16 recurrencies (19%) a strong expression of c-erbB-2 mRNA was detected, in 2 (12%) weak expression was detected, and in 11 (69%) no expression of c-erbB-2 mRNA was detected. Kaplan–Meier analysis revealed no significant association between strong expression of c-erbB-2 mRNA and survival of the 79 patients with primary cancer. However, in the subgroup of patients with FIGO (International Federation of Gynecology and Obstetrics) stages III and IV (n= 60) a shorter median survival time (12 months) was obtained for patients with strong c-erbB-2 mRNA expression compared to patients with no, very weak, and weak c-erbB-2 mRNA expression (25 months,P= 0.04). In addition, strong expression of c-erbB-2 mRNA did not depend on histologic grade, histologic type, and FIGO stage. Adverse prognostic factors include histologic type (serous carcinoma), high grade, high stage (FIGO stages III and IV), and residual of tumor after surgery. From our results we conclude that for all patients (FIGO stages I–IV) strong expression of c-erbB-2 mRNA is not a prognostic parameter, but in the subpopulation of patients with FIGO stage III and IV only, an association between strong c-erbB-2 mRNA expression and shorter median survival time was found, although statistical significance was weak (P= 0.04).</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1006/gyno.1996.0226</identifier><identifier>CODEN: GYNOA3</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>Biological and medical sciences ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Medical sciences ; Tumors</subject><ispartof>Gynecologic oncology, 1996-08, Vol.62 (2), p.268-277</ispartof><rights>1996 Academic Press</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-53e8be06e6268e64e8ca1b7d75d730a370d1e16e116c7bd4ac96ad2a3b24c1af3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3207402$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanner, Berno</creatorcontrib><creatorcontrib>Kreutz, Elisabeth</creatorcontrib><creatorcontrib>Weikel, Wolfgang</creatorcontrib><creatorcontrib>Meinert, Rolf</creatorcontrib><creatorcontrib>Oesch, Franz</creatorcontrib><creatorcontrib>Knapstein, Paul Georg</creatorcontrib><creatorcontrib>Becker, Roger</creatorcontrib><title>Prognostic Significance of c-erbB-2 mRNA in Ovarian Carcinoma</title><title>Gynecologic oncology</title><description>The oncogene specific mRNA of c-erbB-2 was detected by the S1 nuclease protection assay in 95 ovarian cancer specimens. In 79 primary carcinomas, we found 16 (20%) with strong expression, 13 (17%) with weak expression, 4 (5%) with very weak expression, and 46 (58%) with no expression. In 3 of 16 recurrencies (19%) a strong expression of c-erbB-2 mRNA was detected, in 2 (12%) weak expression was detected, and in 11 (69%) no expression of c-erbB-2 mRNA was detected. Kaplan–Meier analysis revealed no significant association between strong expression of c-erbB-2 mRNA and survival of the 79 patients with primary cancer. However, in the subgroup of patients with FIGO (International Federation of Gynecology and Obstetrics) stages III and IV (n= 60) a shorter median survival time (12 months) was obtained for patients with strong c-erbB-2 mRNA expression compared to patients with no, very weak, and weak c-erbB-2 mRNA expression (25 months,P= 0.04). In addition, strong expression of c-erbB-2 mRNA did not depend on histologic grade, histologic type, and FIGO stage. Adverse prognostic factors include histologic type (serous carcinoma), high grade, high stage (FIGO stages III and IV), and residual of tumor after surgery. From our results we conclude that for all patients (FIGO stages I–IV) strong expression of c-erbB-2 mRNA is not a prognostic parameter, but in the subpopulation of patients with FIGO stage III and IV only, an association between strong c-erbB-2 mRNA expression and shorter median survival time was found, although statistical significance was weak (P= 0.04).</description><subject>Biological and medical sciences</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Medical sciences</subject><subject>Tumors</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNp1zz1PwzAQBmALgUQprMweWBPOTuI4A0Op-JIqiviYrYt9qYzauLKrSv33JCpiY7rlfe_uYexaQC4A1O3q0IdcNI3KQUp1wiYCmipTumpO2QSggUzLSp-zi5S-AaAAISfs7i2GVR_Szlv-4Ve977zF3hIPHbcZxfY-k3zz_jrjvufLPUaPPZ9jtL4PG7xkZx2uE139zin7enz4nD9ni-XTy3y2yGwpYJdVBemWQJGSSpMqSVsUbe3qytUFYFGDEyQUCaFs3boSbaPQSSxaWVqBXTFl-XGvjSGlSJ3ZRr_BeDACzIg3I96MeDPih8LNsbDFZHHdxcHk01-rkFCXIIeYPsZoeH7vKZpkPQ185yPZnXHB_3fhB0mWbIs</recordid><startdate>19960801</startdate><enddate>19960801</enddate><creator>Tanner, Berno</creator><creator>Kreutz, Elisabeth</creator><creator>Weikel, Wolfgang</creator><creator>Meinert, Rolf</creator><creator>Oesch, Franz</creator><creator>Knapstein, Paul Georg</creator><creator>Becker, Roger</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19960801</creationdate><title>Prognostic Significance of c-erbB-2 mRNA in Ovarian Carcinoma</title><author>Tanner, Berno ; Kreutz, Elisabeth ; Weikel, Wolfgang ; Meinert, Rolf ; Oesch, Franz ; Knapstein, Paul Georg ; Becker, Roger</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-53e8be06e6268e64e8ca1b7d75d730a370d1e16e116c7bd4ac96ad2a3b24c1af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Biological and medical sciences</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Medical sciences</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanner, Berno</creatorcontrib><creatorcontrib>Kreutz, Elisabeth</creatorcontrib><creatorcontrib>Weikel, Wolfgang</creatorcontrib><creatorcontrib>Meinert, Rolf</creatorcontrib><creatorcontrib>Oesch, Franz</creatorcontrib><creatorcontrib>Knapstein, Paul Georg</creatorcontrib><creatorcontrib>Becker, Roger</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanner, Berno</au><au>Kreutz, Elisabeth</au><au>Weikel, Wolfgang</au><au>Meinert, Rolf</au><au>Oesch, Franz</au><au>Knapstein, Paul Georg</au><au>Becker, Roger</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Significance of c-erbB-2 mRNA in Ovarian Carcinoma</atitle><jtitle>Gynecologic oncology</jtitle><date>1996-08-01</date><risdate>1996</risdate><volume>62</volume><issue>2</issue><spage>268</spage><epage>277</epage><pages>268-277</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><coden>GYNOA3</coden><abstract>The oncogene specific mRNA of c-erbB-2 was detected by the S1 nuclease protection assay in 95 ovarian cancer specimens. In 79 primary carcinomas, we found 16 (20%) with strong expression, 13 (17%) with weak expression, 4 (5%) with very weak expression, and 46 (58%) with no expression. In 3 of 16 recurrencies (19%) a strong expression of c-erbB-2 mRNA was detected, in 2 (12%) weak expression was detected, and in 11 (69%) no expression of c-erbB-2 mRNA was detected. Kaplan–Meier analysis revealed no significant association between strong expression of c-erbB-2 mRNA and survival of the 79 patients with primary cancer. However, in the subgroup of patients with FIGO (International Federation of Gynecology and Obstetrics) stages III and IV (n= 60) a shorter median survival time (12 months) was obtained for patients with strong c-erbB-2 mRNA expression compared to patients with no, very weak, and weak c-erbB-2 mRNA expression (25 months,P= 0.04). In addition, strong expression of c-erbB-2 mRNA did not depend on histologic grade, histologic type, and FIGO stage. Adverse prognostic factors include histologic type (serous carcinoma), high grade, high stage (FIGO stages III and IV), and residual of tumor after surgery. From our results we conclude that for all patients (FIGO stages I–IV) strong expression of c-erbB-2 mRNA is not a prognostic parameter, but in the subpopulation of patients with FIGO stage III and IV only, an association between strong c-erbB-2 mRNA expression and shorter median survival time was found, although statistical significance was weak (P= 0.04).</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><doi>10.1006/gyno.1996.0226</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-8258
ispartof Gynecologic oncology, 1996-08, Vol.62 (2), p.268-277
issn 0090-8258
1095-6859
language eng
recordid cdi_crossref_primary_10_1006_gyno_1996_0226
source ScienceDirect Journals
subjects Biological and medical sciences
Female genital diseases
Gynecology. Andrology. Obstetrics
Medical sciences
Tumors
title Prognostic Significance of c-erbB-2 mRNA in Ovarian Carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T09%3A46%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Significance%20of%20c-erbB-2%20mRNA%20in%20Ovarian%20Carcinoma&rft.jtitle=Gynecologic%20oncology&rft.au=Tanner,%20Berno&rft.date=1996-08-01&rft.volume=62&rft.issue=2&rft.spage=268&rft.epage=277&rft.pages=268-277&rft.issn=0090-8258&rft.eissn=1095-6859&rft.coden=GYNOA3&rft_id=info:doi/10.1006/gyno.1996.0226&rft_dat=%3Celsevier_cross%3ES0090825896902267%3C/elsevier_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c410t-53e8be06e6268e64e8ca1b7d75d730a370d1e16e116c7bd4ac96ad2a3b24c1af3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true